1:25 It is essential that health care practitioners review all data
1:45 To evaluate risk and benefits, unique to each patient
2:11 When determining what health care services to provide,
2:37 Including the administration of covid-19 vaccines
2:53 These decisions should be made on an individual basis (Topic on providing unique care according to individual needs)
3:15 Risk of administering a covid-19 vaccine to healthy children may outweigh the benefits
3:25 Healthy children aged 5 to 17 may not benefit from receiving the currently available COVID-19 vaccine
3:39 Children with underlying conditions are the best candidates for the COVID-19 vaccine Looking at the evidence
4:00 Risk that may outweigh benefits among healthy children with no underlying conditions
4:12 Limited risk of severe illness due to COVID-19
5:00 Keynotes: Paper was used in Delta times, you ideally want something more current. The following are points true according to delta times
5:34 Although Covid-19 is generally milder in children than adults
5:39 Severe illness and long-term complications, including multisystem inflammatory syndrome in children (MIS-C), can occur after primary infection
6:11 Evaluation of the BNT162b2 Covid-19 Vaccine in children 5 to 11 years of AGE (NEJM)
8:42 Argument: There is high prevalence of existing immunity among children
11:18 The absence of data informing benefit of COVID-19 vaccination among children with existing immunity (agrees with the Florida study)
12:19 In clinical trials, higher than anticipated serious adverse events occurred among those receiving the covid-19 vaccine. (reference unclear to this claim)
14:43 Reduced vaccine efficacy in with omicron, Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
16:27 The effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11
16:48 However, vaccination of children 5-11 years was protective against severe disease and is recommended
17:53 Risk of myocarditis due to the COVID-19 vaccine, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (JAMA, 2022)
20:19 Vaccine efficacy wanes rapidly (the percentage drop shown for children and adolescents)
21:40 Recommended for children with underlying health conditions or comorbidities
22:08 In general, healthy children with no significant underlying health conditions under 16 years old are at little to no risk of severe illness complications from covid-19, For adolescents, the risk of myocarditis
